Aflibercept biosimilar is under clinical development by Sam Chun Dang Pharm and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aflibercept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aflibercept biosimilar overview

Aflibercept biosimilar (SCD-411) is under development for the treatment of wet age related macular degeneration. It is administered through intravitreal route. The drug candidate acts by targeting placenta growth factor (PGF), vascular endothelial growth factor A and B (VEGF-A).

Sam Chun Dang Pharm overview

Sam Chun Dang Pharm (SCD) is a manufacturer and distributor of prescription medicines. The company’s products include eyedrops for conjunctivitis, glaucoma, intraocular hypertension and other eye diseases; tablets for treating hypertension, peptic ulcers and diabetics; and injections, syrups and sprays to treat respiratory infections. It offers products in the therapeutic areas of ophthalmology, cardiovascular, endocrinology, gastrointestinal, antibacterials, antifungals, antivirals, respiratory, anti-inflammatories, antihistamines, musculoskeletal and vitamins. The company also conducts research activities for developing drugs to treat diseases such as diabetes and hyperlipidemia. It operates manufacturing facilities in Gyeonggi and Chungcheongbuk, South Korea. SCD is headquartered in Seoul, South Korea.

For a complete picture of Aflibercept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.